Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998-2003)

Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998-2003)

Autor Sader, H. S. Google Scholar
Fritsche, T. R. Google Scholar
Jones, R. N. Google Scholar
Instituição JMI Labs Inc
Universidade Federal de São Paulo (UNIFESP)
Tufts Univ
Resumo We evaluated the antimicrobial spectrum and potency of cefelpitne and selected comparators agents against clinical bacterial strains collected in North America over a 6-year period (1998-2003). Isolates were consecutively collected from bloodstream (44%), respiratory tract (41%), urinary tract (6%), and skin/soft tissue (5%) infections in 48 medical centers. Isolates were susceptibility tested by reference broth microdilution methods in a central laboratory. Oxacillin-resistant staphylococci and enterococci were excluded from the analysis. Imipenem (MIC90 = I mu g/mL, 99.9% susceptible) was the most active compound tested against Enterobacteriaceae (22 860 isolates tested) followed by cefepirne (MIC90 = 0.25 mu g/mL, 99.5% susceptible) > amikacin (99.4% susceptible) > ceftriaxone (95.6% susceptible) > aztreonant (95.1% susceptible). Among comparators, the lowest susceptibility rate for Enterobacteriaceac was observed with ciprofloxacin (92.8% susceptible). Imipenem was also the most active compound against ESBL-producing Klebsiella spp. and Escherichia coli (99.3% and 100% susceptible, respectively), followed by amikacin (81.4% and 97.2% susceptible, respectively) and cefepime (92.5% and 93.8% susceptible, respectively). Cefepime activity against Pseudonionas aeruginosa (85.2% susceptible) was similar to that of imipenem (86.9% susceptible). Against oxacillin-susceptible Staphylococcus aureus, cefepirne (MIC90 = 4 mu g/mL, 100.0% susceptible) was 4-fold more active than ceflazidime (MIC90 = 16 mu g/mL, 86.4% susceptible) and showed a higher susceptibility rate than ciprofloxacin (93.2% susceptible). Cefepime was the most active compound tested against Streptocoecus pneunioniae (MIC90 = 2 mu g/mL, 97.4% susceptible), ranked after gatifloxacin and levofloxacin (99.2% susceptible). the activity of cefepime remained stable during the study period evaluated with the susceptibility rates varying from 99.3% to 99.8% among the Enterobacteriaceae and 84.4% to 88.4% among P aeruginosa isolates. in summary, cefepime has retained broad activity and spectrum against Enterobacteriaceae, P aeruginosa, and Gram-positive cocci (except oxacillin-resistant staphylococci and enterococci) isolated from North American medical centers in the 1998-2003 period. Continued resistance Surveillance is critical to monitor the effectiveness of widely used parenteral antimicrobial agents such as cefepime. (c) 2005 Elsevier Inc. All rights reserved.
Palavra-chave cefepime
Enterobacteriaceae
Pseudomonas aeruginosa
Streptococcus pneumoniae
cephalosporin
Idioma Inglês
Data de publicação 2005-07-01
Publicado em Diagnostic Microbiology and Infectious Disease. New York: Elsevier B.V., v. 52, n. 3, p. 265-273, 2005.
ISSN 0732-8893 (Sherpa/Romeo, fator de impacto)
Publicador Elsevier B.V.
Extensão 265-273
Fonte http://dx.doi.org/10.1016/j.diagmicrobio.2005.02.003
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000232236700015
Endereço permanente http://repositorio.unifesp.br/handle/11600/28371

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta